Cancers 2011, 3(2), 2554-2596; doi:10.3390/cancers3022554

State of the Art in Tumor Antigen and Biomarker Discovery

INSERM U624, 163 avenue de Luminy, 13288 Marseille Cedex 09, France
* Author to whom correspondence should be addressed.
Received: 6 April 2011; in revised form: 24 May 2011 / Accepted: 27 May 2011 / Published: 9 June 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
PDF Full-text Download PDF Full-Text [417 KB, uploaded 9 June 2011 09:58 CEST]
Abstract: Our knowledge of tumor immunology has resulted in multiple approaches for the treatment of cancer. However, a gap between research of new tumors markers and development of immunotherapy has been established and very few markers exist that can be used for treatment. The challenge is now to discover new targets for active and passive immunotherapy. This review aims at describing recent advances in biomarkers and tumor antigen discovery in terms of antigen nature and localization, and is highlighting the most recent approaches used for their discovery including “omics” technology.
Keywords: tumor antigen; biomarkers; immunotherapy; cancer; proteomics

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Even-Desrumeaux, K.; Baty, D.; Chames, P. State of the Art in Tumor Antigen and Biomarker Discovery. Cancers 2011, 3, 2554-2596.

AMA Style

Even-Desrumeaux K, Baty D, Chames P. State of the Art in Tumor Antigen and Biomarker Discovery. Cancers. 2011; 3(2):2554-2596.

Chicago/Turabian Style

Even-Desrumeaux, Klervi; Baty, Daniel; Chames, Patrick. 2011. "State of the Art in Tumor Antigen and Biomarker Discovery." Cancers 3, no. 2: 2554-2596.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert